Be the first person to write a business review for Whatman plc

The Whitehead Institute for Biomedical Research blazes new trails in bioscience. The organization, funded by both the public and private sectors, investigates such diseases as Parkinson's and cancer and dives into the depths of biology, genomics, and genetics to gain new understanding about disease and health. The Whitehead Institute contributed to the international effort to map the human genome, and is actively researching stem cells. Other achievements include discovering a system for multiplying adult stem cells and creating the first genetically defined human cancer cell. The institute was founded in 1982 by philanthropist Edwin "Jack" Whitehead and draws researchers from MIT.

Xceed Molecular is working to exceed the expectations of researchers performing gene expression tests. The company's flow-thru chip technology allows biotechnology and pharmaceutical companies to conduct genetic screening research. Its Ziplex system is used for automated gene expression analysis. Other products include assay reagent kits, sample preparation reagents, and its TipChip disposable microarrays. The company also produces chips to detect specific diseases and is working to speed up the time needed to process samples. Xceed Molecular, which was established in 2001, has facilities in Canada and the US.

Xencor, Inc. company tailors proteins, not pants. Xencor is developing therapeutics for cancer, inflammatory ailments, and autoimmune diseases. The company engineers antibodies using its Protein Design Automation (PDA) technology, which allows for the specific targeting of diseased cells. Its drug candidates aim to treat cancerous conditions such as Hodgkin's lymphoma, T-cell lymphomas, and B-cell malignancies, as well as other autoimmune diseases. Research partners include Centocor, Genentech, Eli Lilly, and Human Geonome Sciences.

XenoPort, Inc. company was founded in 1999 and is based in Santa Clara, California. XenoPort, Inc., a biopharmaceutical company, focuses on developing internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. Its portfolio of product candidates includes XP13512, which is a transported prodrug of gabapentin, has been evaluated in a phase III clinical program for the treatment of restless legs syndrome, as well as completed a phase IIa clinical trial for the management of post-herpetic neuralgia; XP19986, a transported prodrug of R-baclofen for the treatment of gastroesophageal reflux disease and spasticity; and XP21279, a transported prodrug of levodopa, which is in phase I clinical trial for the treatment of Parkinson's disease. The company also develops XP21279, a transported prodrug of L-Dopa, for the treatment of Parkinson's disease; and XP21510, a transported prodrug of tranexamic acid, for the treatment of menorrhagia or heavy menstrual bleeding. XenoPort has strategic alliances with Astellas Pharma, Inc.; Glaxo Group Limited; and Xanodyne Pharmaceuticals, Inc.

XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California. XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohn's disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and gout, which is in Phase 1 clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The company's developing products also include HCD122, a human anti-CD40 antagonist antibody for the treatment for B-cell mediated diseases, including malignancies and autoimmune diseases in Phase 1 and Phase 2 clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Genentech, Inc.; UCB Celltech; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.